AstraZeneca Wins Final Nod For $39B Alexion Deal
AstraZeneca overcame the final regulatory hurdle to its planned $39 billion acquisition of fellow drugmaker Alexion Pharmaceuticals Inc., after the U.K.'s competition enforcer cleared the deal unconditionally on Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article